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         尿中グルコ糖酸の臨床的意義
特にXylito1静注後の尿中グルコ糖酸の変動．とそれに
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   Since these 3 or 4 years the interrelationship between glucaric acid・and 3－glucuronidase in
urine has been stressed in Japan ； and considerably many investigators have・regarded the urinary
glucaric acid as an index of inhibitory agents to p－glucuronidase ip urine， the conversion
rate of glucosaccharo 1．4， 3・6 dilactone into glucaric acid as an index to distinguish bladder
cancer from others， and the programmed increase of urinary glucaric acid as an excellent
therapeutic m6thod of bladder cancer． To confirm these findings and hypothesis， a series． of
clinical studies were carried out and the following results were obtained．
   1． The decreased excretion ’of glucaric acid in urine and the decreased conversion rate
of glucosaccharo 1．4， 3．6 dilactone into glucaric acid in urine were considered as the
chqracteristics of bladder．cancer， but were found， also， in traumatic paraplegics． So it was
diMcult to say these findings were specific i．n carcinoma of’the bladder．
   2． Suppression of urinary glucaric acid after glucosaccharo 1 ． 4，．3 ． 6 dilactone or glucurono－
lactone adminiStration was observed in some of traumatic paraplegics． lt was di’fficult to
explain these findings by the present metabolic map．
   3． ．Marked decrease of glucaric acid in urine ensued after intravenous administration
of xylitol 50 g （10％ 500 ml） in almost・ all of the．cases．
   4． Urinary P－glucuronidase aetiVities were decreased in about half・ of cases administered
glucQsaccharo 1．4， 3．6 dilactone and xylitol．
   5． Xylitol administration resulted’in the decreasie of urinary P－glucuronidase accompanied
with the decrease of urinary glucaric acid． lf the above－mentioned hypothesis that glucaric
acid was an index of P－glucuronidase inhibition were valid， it would’be impossible to explain
these findings． So it was rather rational to consider that glucaric acid and B－glucuronidase in
uri4e were ・independent each other． Namely， the close interrelationship between glucaric acid




































































 （6） Column chromatography
  （i）Dowex l x－8 borateのcolumnに検体
  を加える（15～60分）．
  （ii）0．05M Na2B407十〇．02M Na2SO4混合の第
  1液150m1で流す（70～80分）．



















                近藤他：尿中グルコ糖酸の臨床的意義             217





















Table 2 SLA－GLA Conversion Rate
62






















皿 SLA－GLA Conversion Rate合 計 6／






  Conversion rate＝L’一C ＞dOO70Eo’
            c
   a；投与前24時問尿中GLA（mg／日）
   b：投与後24時間尿中GLA（mg／日）
   c＝投与全量がGLAになった場合の計算量








 算出式はSLD 1，000 mg＝SLA 1，500 mg＝GLA
1，200mgという関係があり，SLA 3，000mg投与を行
なっためで次のごとくである．



















IV GL－GLA Conyersion Rate
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Fig， 1 Pathways of Carbohydrate Metabolisrn．
率は次のごとくである．
















れたGLはG工ucaric acid pathwayよりも， Uronic
acid pathwayにもっぱら進んだのであろうと考えら
れる（Fig．1）．











    V Xylitol静注と尿中GLA
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はPentose phosphate pathwayのd－Xylulose 5P
に向かう場合と Embden Myerhof pathwayの
UDPGに向かう場合と Glucaric acid pathwayセこ
向かう場合とが考えられる．Xylito1静注により恐ら
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